Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: Gemini who wrote (979)	7/10/2000 9:56:26 PM
From: Mama Bear	Read Replies (1) \| Respond to of 1298

ABGX shares are not cash equivalents. There would be income tax to pay as they are pretty close to out of NOL's because of the sale of ABGX shares earlier this year, there would be transaction fees, and it would be necessary to discount them to the market. There would also likely be some pressure on ABGX shares leading up to the sale. A trade like that doesn't go off at the click of a mouse. Also, I believe you counted ABGX twice, as the $587 million figure includes that stake, at 3/31/00 value. You also can't forget to include the debit side of the balance sheet in your calculations. edgar-online.com Regardless, it is still a very healthy balance sheet for a young company. Regards, Barb

To: Gemini who wrote (979)	7/10/2000 11:02:59 PM
From: EightyEight	Read Replies (1) \| Respond to of 1298

I thought they had 350 million in cash. That's from filings and a recent confirmation from IR (three weeks ago). Anyway you add it up, they've got very deep pockets. 88